Velan Capital Investment Management’s Neumora Therapeutics NMRA Stock Holding History

Velan Capital Investment Management’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$156K	Buy	+80,000	New	+$207K	0.1%	40

Other funds holding NMRA

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Velan Capital Investment Management's NMRA Position: Q1 2026 in Review

Velan Capital Investment Management opened a new position in Neumora Therapeutics (NMRA) in Q1 2026: 80,000 shares worth $156K. The stake represents 0.1% of the portfolio and ranks #40 among its holdings.

114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

Velan Capital Investment Management held 80,000 shares of Neumora Therapeutics worth $156K as of Q1 2026.
Neumora Therapeutics was a new Velan Capital Investment Management position in Q1 2026.
Neumora Therapeutics made up 0.1% of Velan Capital Investment Management's portfolio in Q1 2026, its #40 holding.
114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.